• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VHL
Click for more information
7.69% 14.0¢

VIRAX HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
VHL Prescient completes acquisition of AKTivate TherapeuticsPRICE SENSITIVE11/12/14
VHL Appendix 4C - quarterlyPRICE SENSITIVE03/11/14
VHL VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIOPRICE SENSITIVE17/10/14
VHL Trading HaltPRICE SENSITIVE15/10/14
VHL FDA IND Re-Activation Request for Phase Ib/II TrialPRICE SENSITIVE09/09/14
VHL Virax Holdings Appendix 4E and 2014 Financial ReportPRICE SENSITIVE01/09/14
VHL Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
VHLVHL completes Pathway acquisiton, appoints new directorPRICE SENSITIVE30/05/14
VHLAppointment of Managing Director to Drive Cancer ProgramsPRICE SENSITIVE15/05/14
VHLDisclosure DocumentPRICE SENSITIVE14/05/14
VHLCapital Raising UpdatePRICE SENSITIVE09/05/14
VHLVirax Option to Acquire Exclusive Worldwide LicencePRICE SENSITIVE05/05/14
VHLTrading HaltPRICE SENSITIVE01/05/14
VHLAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
VHLCo-X-Gene Development PipelinePRICE SENSITIVE24/04/14
VHLVirax secures $3 million placementPRICE SENSITIVE25/03/14
VHLTrading HaltPRICE SENSITIVE21/03/14
VHLVirax to acquire advanced cancer platform from Yale UniPRICE SENSITIVE17/03/14
VHLTrading HaltPRICE SENSITIVE14/03/14
VHLHalf Yearly Report and AccountsPRICE SENSITIVE28/02/14
VHLIntellectual Property Report UpdatePRICE SENSITIVE19/02/14
VHLResponse to ASX Aware LetterPRICE SENSITIVE12/02/14
VHLTransgene Announces Topline Preliminary ResultsPRICE SENSITIVE07/02/14
VHLReinstatement to Official Quotation - 19 November 2013PRICE SENSITIVE18/11/13
AAY +Suspension from Official QuotationPRICE SENSITIVE01/03/12
VHLDutchess Continuous Investment Agreement - 10 January 2012PRICE SENSITIVE10/01/12
VHLSuspension from Official Quotation - VHLGPRICE SENSITIVE21/12/11
VHLAppendix 4E 30 June 2011PRICE SENSITIVE31/08/11
VHLTG1042 Batch Manufacturing Completed - 26 July 2011PRICE SENSITIVE26/07/11
VHLRights Offer - 19 July 2011PRICE SENSITIVE19/07/11
VHLTG1042 Update - MelanomaPRICE SENSITIVE10/06/11
VHLEligible Shareholder Offer Document Mailing - 6 June 2011PRICE SENSITIVE06/06/11
VHLVirax Rights Offer Documentation - 25 May 2011PRICE SENSITIVE25/05/11
VHL1 for 2 Rights Offer - 25 May 2011PRICE SENSITIVE25/05/11
VHLAppendix 4D (31 Dec 2010) - 25 February 2011PRICE SENSITIVE25/02/11
VHLCo-X-Gene Sub Licence and TG4001 - 24 February 2011PRICE SENSITIVE24/02/11
VHLVirax close out of VIR201 HIV Vaccine Phase IIa TrialPRICE SENSITIVE23/02/11
VHLExclusive License with Transgene for Novel Skin Cancer ImmunPRICE SENSITIVE14/02/11
VHLTerms Sheet - Skin CancerPRICE SENSITIVE12/11/10
VHLAppendix 4EPRICE SENSITIVE31/08/10
VHLVIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010PRICE SENSITIVE16/08/10
VHLVIR201 HIV Vaccine published in AIDS JournalPRICE SENSITIVE12/08/10
VHLUpdate on VIR201 HIV Vaccine Clinical Trial - 9 August 2010PRICE SENSITIVE09/08/10
VHLUpdate on VIR201 HIV Vaccine Clinical TrialPRICE SENSITIVE07/07/10
VHLTransgene TG4010 Exclusive OptionPRICE SENSITIVE11/03/10
VHLAppendix 4D - Half Year 31 December 2009PRICE SENSITIVE26/02/10
VHLResponse to ASX Price QueryPRICE SENSITIVE23/02/10
VHLConvertible Notes - Quarterly Report - 29 January 2010PRICE SENSITIVE29/01/10
VHLSubsequent Placement Announcement - 23 Dec 09PRICE SENSITIVE23/12/09
VHLNon-renounceable Rights Offer Shortfall Placement AgreementsPRICE SENSITIVE16/12/09
VHLFurther Patent Protection for VIR201PRICE SENSITIVE10/12/09
VHLUS FDA Fast Track Approval of Transgene TG4010PRICE SENSITIVE03/12/09
VHLEntitlement OfferPRICE SENSITIVE23/11/09
VHLDSMB Review - 19 Nov 2009PRICE SENSITIVE19/11/09
VHLPreliminary Final Report - Appendix 4E - 30 June 2009PRICE SENSITIVE28/08/09
VHLShareholder Update - 13 August 2009PRICE SENSITIVE13/08/09
VHLConvertible Note Quarterly Report 30 06 2009PRICE SENSITIVE31/07/09
VHLIdentification of Novel Immune Mechanism - VIR201PRICE SENSITIVE22/07/09
VHLVirax South African Trial UpdatePRICE SENSITIVE17/06/09
VHLTransgene TG4010 UpdatePRICE SENSITIVE11/06/09
VHLPrivate PlacementPRICE SENSITIVE20/05/09
VHLConvertible Note Quarterly Report - 31 March 2009PRICE SENSITIVE30/04/09
VHLAppendix 4D 31 December 2008PRICE SENSITIVE27/02/09
VHLTransgene TG4010 UpdatePRICE SENSITIVE19/02/09
VHLVirax Share Purchase Plan - January 2009PRICE SENSITIVE22/01/09
VHLVIR201 South African Trial First patient VaccinatedPRICE SENSITIVE11/12/08
VHL Prescient completes acquisition of AKTivate Therapeutics
11/12/14PRICE SENSITIVE
VHL Appendix 4C - quarterly
03/11/14PRICE SENSITIVE
VHL VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIO
17/10/14PRICE SENSITIVE
VHL Trading Halt
15/10/14PRICE SENSITIVE
VHL FDA IND Re-Activation Request for Phase Ib/II Trial
09/09/14PRICE SENSITIVE
VHL Virax Holdings Appendix 4E and 2014 Financial Report
01/09/14PRICE SENSITIVE
VHL Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
VHLVHL completes Pathway acquisiton, appoints new director
30/05/14PRICE SENSITIVE
VHLAppointment of Managing Director to Drive Cancer Programs
15/05/14PRICE SENSITIVE
VHLDisclosure Document
14/05/14PRICE SENSITIVE
VHLCapital Raising Update
09/05/14PRICE SENSITIVE
VHLVirax Option to Acquire Exclusive Worldwide Licence
05/05/14PRICE SENSITIVE
VHLTrading Halt
01/05/14PRICE SENSITIVE
VHLAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
VHLCo-X-Gene Development Pipeline
24/04/14PRICE SENSITIVE
VHLVirax secures $3 million placement
25/03/14PRICE SENSITIVE
VHLTrading Halt
21/03/14PRICE SENSITIVE
VHLVirax to acquire advanced cancer platform from Yale Uni
17/03/14PRICE SENSITIVE
VHLTrading Halt
14/03/14PRICE SENSITIVE
VHLHalf Yearly Report and Accounts
28/02/14PRICE SENSITIVE
VHLIntellectual Property Report Update
19/02/14PRICE SENSITIVE
VHLResponse to ASX Aware Letter
12/02/14PRICE SENSITIVE
VHLTransgene Announces Topline Preliminary Results
07/02/14PRICE SENSITIVE
VHLReinstatement to Official Quotation - 19 November 2013
18/11/13PRICE SENSITIVE
AAY +Suspension from Official Quotation
01/03/12PRICE SENSITIVE
VHLDutchess Continuous Investment Agreement - 10 January 2012
10/01/12PRICE SENSITIVE
VHLSuspension from Official Quotation - VHLG
21/12/11PRICE SENSITIVE
VHLAppendix 4E 30 June 2011
31/08/11PRICE SENSITIVE
VHLTG1042 Batch Manufacturing Completed - 26 July 2011
26/07/11PRICE SENSITIVE
VHLRights Offer - 19 July 2011
19/07/11PRICE SENSITIVE
VHLTG1042 Update - Melanoma
10/06/11PRICE SENSITIVE
VHLEligible Shareholder Offer Document Mailing - 6 June 2011
06/06/11PRICE SENSITIVE
VHLVirax Rights Offer Documentation - 25 May 2011
25/05/11PRICE SENSITIVE
VHL1 for 2 Rights Offer - 25 May 2011
25/05/11PRICE SENSITIVE
VHLAppendix 4D (31 Dec 2010) - 25 February 2011
25/02/11PRICE SENSITIVE
VHLCo-X-Gene Sub Licence and TG4001 - 24 February 2011
24/02/11PRICE SENSITIVE
VHLVirax close out of VIR201 HIV Vaccine Phase IIa Trial
23/02/11PRICE SENSITIVE
VHLExclusive License with Transgene for Novel Skin Cancer Immun
14/02/11PRICE SENSITIVE
VHLTerms Sheet - Skin Cancer
12/11/10PRICE SENSITIVE
VHLAppendix 4E
31/08/10PRICE SENSITIVE
VHLVIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010
16/08/10PRICE SENSITIVE
VHLVIR201 HIV Vaccine published in AIDS Journal
12/08/10PRICE SENSITIVE
VHLUpdate on VIR201 HIV Vaccine Clinical Trial - 9 August 2010
09/08/10PRICE SENSITIVE
VHLUpdate on VIR201 HIV Vaccine Clinical Trial
07/07/10PRICE SENSITIVE
VHLTransgene TG4010 Exclusive Option
11/03/10PRICE SENSITIVE
VHLAppendix 4D - Half Year 31 December 2009
26/02/10PRICE SENSITIVE
VHLResponse to ASX Price Query
23/02/10PRICE SENSITIVE
VHLConvertible Notes - Quarterly Report - 29 January 2010
29/01/10PRICE SENSITIVE
VHLSubsequent Placement Announcement - 23 Dec 09
23/12/09PRICE SENSITIVE
VHLNon-renounceable Rights Offer Shortfall Placement Agreements
16/12/09PRICE SENSITIVE
VHLFurther Patent Protection for VIR201
10/12/09PRICE SENSITIVE
VHLUS FDA Fast Track Approval of Transgene TG4010
03/12/09PRICE SENSITIVE
VHLEntitlement Offer
23/11/09PRICE SENSITIVE
VHLDSMB Review - 19 Nov 2009
19/11/09PRICE SENSITIVE
VHLPreliminary Final Report - Appendix 4E - 30 June 2009
28/08/09PRICE SENSITIVE
VHLShareholder Update - 13 August 2009
13/08/09PRICE SENSITIVE
VHLConvertible Note Quarterly Report 30 06 2009
31/07/09PRICE SENSITIVE
VHLIdentification of Novel Immune Mechanism - VIR201
22/07/09PRICE SENSITIVE
VHLVirax South African Trial Update
17/06/09PRICE SENSITIVE
VHLTransgene TG4010 Update
11/06/09PRICE SENSITIVE
VHLPrivate Placement
20/05/09PRICE SENSITIVE
VHLConvertible Note Quarterly Report - 31 March 2009
30/04/09PRICE SENSITIVE
VHLAppendix 4D 31 December 2008
27/02/09PRICE SENSITIVE
VHLTransgene TG4010 Update
19/02/09PRICE SENSITIVE
VHLVirax Share Purchase Plan - January 2009
22/01/09PRICE SENSITIVE
VHLVIR201 South African Trial First patient Vaccinated
11/12/08PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
US election outcomes: Key economic and market takeaways This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.